NRx Pharmaceuticals, Inc. (NRXP)
After hours:
- GlobeNewswire
NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guidelinesNRx is also making ZYESAMI available as an investigational medicine under the Federal Right to Try Act1ZYESAMI is available to patients who have progressed despite treatment with remdesivir and other approved medicines and who are not able
- GlobeNewswire
NRx Responds to Relief’s Allegations of January 14, 2022
Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil fines against Dr. John Paul Waymack, and a prior securities fraud conviction, incarceration, and SEC fines against Adam Gottbetter.NRx provided all financial records to Relief on December 6, 2021, yet Relief advised the SEC on December 16, 2021, that it received no records from NRx.NRx looks forward to
- GlobeNewswire
NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant
Trial targeted to begin in the first quarter of 2022NRx is coordinating study with the US Health and Human Services Biomedical Advanced Research and Development Authority and several European GovernmentsIsrael Ministry of Health has approved first-in-human trial of intradermal BriLife vaccination with the objective of enhancing immune responseNRx continues technology transfer and scale up activities in anticipation of GMP manufacture RADNOR, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuti
